Highest-materiality recent filing
Director Xinliang Li resigns from AiXin Life board and audit chair role
Mr. Xinliang Li resigned as director and from Compensation, Nominating, and Audit Committee roles effective May 18, 2026.
AiXin Life appoints Qiyu Jiang as director and secretary, effective April 15, 2026
Qiyu Jiang, 40, appointed as director and Secretary of AiXin Life and its subsidiaries.
Director Yao-te Wang resigns from board and all officer roles at AiXin Life International
Board accepted resignation of Yao-te Wang effective January 26, 2026.
Aixin Life restates 2021 results; net loss widens from $267K to $1.18M
FY2021 net loss restated to $1,176,568 from originally reported $267,236.
Aixin Life restating 2021 financials; auditor flagged acquisition accounting
Restating 2021 financials after former auditor KCCW identified need to correct acquisition accounting for two 2021 deals.
Aixin Life International to restate 2021 financials for common-control acquisitions
Company to restate 2021 financials due to accounting for acquisitions of Aixin Shangyan Hotel and Aixintang Pharmacies as entities under common control.
AiXin Life International appoints YCM CPA INC. as new auditor for FY 2024
Board approved retention of YCM CPA INC. as independent auditor for year ending Dec 31, 2024 on Feb 10, 2025.
AiXin Life International's auditor KCCW resigns effective Jan 7, 2025; no disagreements reported
KCCW Accountancy Corp. resigned as AiXin Life’s independent auditor, effective January 7, 2025.
AiXin Life International CFO Tianfeng Li resigns; Xiaowen Zheng appointed CFO
Tianfeng Li resigned as CFO on Jan 5, 2025 effective same day; no disagreement with company's accounting or policies.
AiXin Life receives OTCQX deficiency notice for late 10-K; faces delisting if not cured by May 18
Received OTCQX deficiency notice on April 18, 2023 for failure to file 10-K for year ended Dec 31, 2022.
AiXin Life reports FY 2022 revenue $2.7M (-11.7% YoY); operating loss $2.6M; cash plummets to $510K
Sales revenue $2.7M, down 11.7% vs 2021; advertising revenue zero in 2022 vs $1.9M in 2021.
AiXin Life International announces 1-for-2 reverse stock split effective Feb 17, 2023
Reverse stock split ratio: 1-for-2; every two shares convert to one share.
AiXin Life shareholders elect directors and ratify auditor at annual meeting
Elected Quanzhong Lin (32,840,642 votes for), Yao-Te Wang (32,839,692), Christopher Lee (32,839,692), Huiliang Jiao (32,839,706) as directors.
AiXin Life files amendment for 1-for-2 reverse stock split, subject to FINRA approval
Amendment filed Jan 6, 2023; each two pre-split shares combine into one new share.
AiXin Life appoints Tianfeng Li as CFO; Jiao Huiliang to Board; Chang-Ping Lin resigns
Tianfeng Li appointed CFO effective December 1, 2022, replacing Guolu Li.
Aixin Life appoints Tianfeng Li as CFO and Jiao Huiliang to Board
Tianfeng Li appointed CFO effective Dec 1, 2022; base salary $26,000 annually.
Aixin Life reduces acquisition price for Yunnan Runcansheng to RMB 31.6M (USD 4.55M)
Original price of RMB 45.08M reduced to RMB 31.56M (approx US$4.55M) per Supplementary Agreement 2.
AiXin Life completes acquisition of Yunnan Runcansheng, effective Sept 30, 2022
Assumed operational control of Yunnan Runcansheng Technology; transfer effective Sept 30, 2022.
Yunnan Runcansheng revenue $783,149, net loss $35,765 for year ended Dec 31, 2021.
Aixin Life to acquire Yunnan Runcansheng for RMB 45.1M; conditions include net worth threshold
Purchase price RMB 45,082,600 for 100% equity; deposit of RMB 5M paid, RMB 15M escrowed.
Shangyan Co revenue $748,056 for six months ended June 30, 2021; net loss $481,453.
Aixin Life files financial statements for acquired pharmacies; shows 2020 net loss of $185K
Acquired entity Chengdu Aixintang Pharmacy (9 pharmacies) had 2020 revenue of $1.26M and net loss of $185K.
Acquired hotel's 2020 revenue $1.07M, net loss $689K; equity deficit $1.47M
2020 revenue $1.07M, down 37% YoY from $1.71M; net loss $689K vs $384K in 2019.
Aixin Life stockholders approve all four proposals at 2021 annual meeting
Elected directors: Quanzhong Lin (39.96M for), Yao-Te Wang (39.95M for), Chang-Ping Lin (39.90M for), Christopher Lee (39.92M for); 2.09M broker non-votes.
Effective May 18, 2026, Aixin Life International, Inc. (the “Company”) accepted the resignation of Mr. Xinliang Li a/k/a Christopher Lee from the Company’s Board of Directors.
Effective January 6, 2025, Mr. Xiaowen Zheng, 39 years old, was appointed by the Board of Directors (the “Board”) of the Company to the position of Chief Financial Officer of the Company.
On January 5, 2025, Ms. Tianfeng Li, the Chief Financial Officer of Aixin Life International, Inc. (the “Company”), tendered her resignation as Chief Financial Officer of the Company, effective January 5, 2025.
Resignation of Tianfeng Li as Chief Financial Officer and Director
the Company accepted the resignation of Mr. Chang-Ping Lin from the Company’s Board of Directors.
the appointment of Mr. Jiao Huiliang to the Company’s Board of Directors
the appointment of Ms. Tianfeng Li to replace Guolu Li as the Company’s Chief Financial Officer, effective December 1, 2022
Effective December 1, 2022, Ms. Tianfeng Li, 35 years old, was appointed by the Board of Directors of Aixin Life International, Inc. to the position of Chief Financial Officer of the Company.
Effective December 1, 2022, Mr. Jiao Huiliang was added to the Board of Directors of our Company.
Ms. Li replaces Guolu Li who had been serving as our Chief Financial Officer since February 2017.
Max materiality 0.85 · Median 0.50 · Most common event other_material